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Purpose: To describe a combination of treatment modalities used for the successful eradication 
of Fusarium endophthalmitis.
Design: Interventional case series.
Participants: Three consecutive patients with keratitis-associated Fusarium endophthalmitis.
Methods: After failure of traditional management options, a combination of intravitreal and 
long-term, high-dose systemic voriconazole, topical antifungal medications, and surgical 
intervention, with penetrating keratoplasty, lensectomy, and endoscopic-guided pars plana 
vitrectomy, was administered to each patient.
Results: All three cases achieved full resolution of the infection, with a final Snellen visual 
acuity score of 20/50 to 20/70.
Conclusions: An aggressive combination of therapeutic modalities, including the 
removal of subiris abscesses, might be needed for the successful resolution of Fusarium 
endophthalmitis.
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Introduction
Fusarium is a saprotrophic mold, with worldwide distribution, that is responsible for 
destructive mycotic keratitis. In portions of the Southern United States,   keratomycosis 
accounts for 6% of all microbial keratitis cases, and Fusarium species comprise 62% of 
fungal isolates.1 Although cases are often associated with trauma,1,2 a 2006   international 
outbreak of Fusarium keratitis, secondary to ReNu with MoistureLoc contact 
lens   cleaning solution (Bausch and Lomb, Rochester, NY), produced at least 130 
  confirmed cases in the United States alone.3 Two cases of contact lens-induced keratitis, 
progressing to endophthalmitis, were reported due to this outbreak.4
Fusarium is visually destructive, due to its high rates of resistance against 
many   antifungal mediations,5 relentless infiltration into ocular tissues,6 mycotoxic-
ity,7,8 and intravascular invasion with occlusion.9 It can perforate the cornea and 
produce an infiltrative endophthalmitis in over 6% of keratitis cases, which leaves at 
least 60% of eyes with finger-counting or worse visual acuity, and 30% of eyes with 
  phthisis, or requiring enucleation.6,10 This manuscript will describe the clinical course 
and   successful resolution of three consecutive cases of Fusarium endophthalmitis 
secondary to keratitis. Two of the cases were the result of soft contact lens wearing; 
the final case resulted from traumatic injury to the cornea. All three cases illustrate 
a uniform combination of treatments, involving the removal of subiris abscesses, to 
sterilize the eye and achieve a Snellen visual acuity of 20/50 to 20/70.
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Methods
Review of patient records was approved by the Institutional 
Review Board of the University of Michigan, and conforms to 
all privacy rules set forth by the Health Insurance Portability 
and Accountability Act.
Case 1
A 32-year-old healthy female contact lens wearer was referred 
to the Cornea Service at our academic ophthalmology 
institution with a 10-day history of increasing redness, pain, 
and blurring of vision in the right eye. She had previously 
started treatment with topical ofloxacin (0.3%) and 
prednisolone acetate (1%). At presentation, the examination 
revealed a Snellen visual acuity of 20/20 with a medium-
sized superficial corneal ulcer and indistinct infiltrate at the 
margins. Corneal cultures were obtained, and prednisolone 
acetate treatment was immediately discontinued. Three days 
after presentation, an emergent penetrating keratoplasty was 
required for a corneal perforation. The cultures revealed 
unspeciated Fusarium. The patient began treatment with 
frequent topical natamycin (5%), amphotericin B deoxycholate 
(0.15%), as well as oral ketoconazole (200 mg per day). 
Prednisolone acetate (1%) was also prescribed to prevent 
graft rejection. Two weeks later, the patient was referred to the 
Retina Service because of increased corneal graft infiltration 
and anterior segment inflammation with a new hypopyon. 
Due to presumed intraocular invasion of Fusarium, 5 µg of 
amphotericin B deoxycholate was injected into the vitreous, 
and oral voriconazole (VFEND®, Pfizer, New York, NY) 
(200 mg two times per day) was substituted for ketoconazole. 
The eye continued to worsen clinically over 4 days, with the 
development of vitreous opacities on B-scan ultrasound. 
An emergent 20-gauge pars plana vitrectomy, with cultures 
and lensectomy, was performed with a repeat intraocular 
injection of amphotericin B deoxycholate (5 µg) at the 
conclusion of surgery. The cultures reconfirmed unspeciated 
Fusarium, and were sent to another institution for sensitivity 
analysis. Initial postoperative improvement was quickly 
supplanted by increasing intraocular inflammation, and the 
eye received a third pars plana injection of amphotericin 
B deoxycholate (5 µg), followed by two injections of 
voriconazole (100 µg). However, intraocular inflammation 
continued to worsen. A second vitrectomy was performed, 
using endoscopic guidance because of significant corneal graft 
edema. The camera revealed large subiris and ciliary body 
abscesses, which were removed with the vitrectomy cutter 
(see Video http://youtu.be/SLvTMCQB8X0). A third 
intravitreal voriconazole injection (100 µg) was given at the 
conclusion of the surgery. Shortly afterwards, culture sensitivity 
results revealed resistance to amphotericin B deoxycholate 
and ketoconazole. In addition, the minimum inhibitory 
concentration (MIC) of voriconazole was .8 µg/mL, which 
suggested poor sensitivity. Because of this high MIC and 
the difficulty eradicating the infection previously, a fourth 
intravitreal voriconazole (100 µg) injection was given 
shortly after surgery, in addition to increasing the dose of 
oral voriconazole to 400 mg twice-daily. The eye showed 
slow clinical improvement. The high-dose oral voriconazole 
and topical natamycin were discontinued after 3 months. 
A repeat penetrating keratoplasty was later required due 
to graft failure. The Snellen best-corrected visual acuity 
measured 20/70 after 5 years of follow-up.
Case 2
A 48-year-old healthy female contact lens wearer was 
referred to the Cornea Service at our institution with a 
7-day history of increased redness, pain, and blurring 
of vision in the right eye. She had previously started 
treatment with a topical combination of tobramycin (0.3%) 
and dexamethasone (0.1%). At presentation, examination 
revealed a Snellen visual acuity of 20/400 with a central 
corneal ulcer and underlying infiltrate. A corneal smear 
revealed filamentous elements. Dexamethasone and 
tobramycin were discontinued, and topical natamycin 
(5%), amphotericin B deoxycholate (0.15%), and oral 
voriconazole (200 mg per day) were initiated. The cultures 
revealed unspeciated Fusarium. Two weeks later, the patient 
was referred to the Retina Service because of increased 
corneal infiltration and anterior segment inflammation with 
a new hypopyon (Figure 1A). Voriconazole (100 µg) was 
injected through the pars plana, and the oral voriconazole 
was increased to 400 mg twice-daily. However, new vitreous 
opacities on B-scan ultrasonography and worsening 
anterior segment inflammation precipitated a penetrating 
keratoplasty, 20-gauge pars plana vitrectomy with cultures, 
lensectomy, and endoscopic exploration 2 days later. 
Subiris and ciliary body abscesses were visualized and 
excised during surgery. The surgical cultures failed to yield 
organisms. However, histology of the extracted corneal 
button revealed persistent fungal elements. The intraocular 
inflammation slowly improved. However, an infiltrate 
at the graft-host interface was suspicious for recurrent 
infection, and topical voriconazole (1%) was added to 
the topical natamycin (5%), amphotericin B deoxycholate   
(0.15%), and prednisolone acetate (1%) regimen. Despite 
this, the corneal infiltrate continued to worsen and required 
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a second penetrating keratoplasty. The corneal button was 
negative for fungal elements. Four months postoperatively, 
the eye had no signs of recurrent infection (Figure 1B), 
and the oral voriconazole was discontinued along with the 
topical antifungal medications. The Snellen best-corrected 
visual acuity was 20/50 at 1.5 years of follow-up.
Case 3
A 54-year-old healthy male was referred to the Cornea Service 
at our institution 4 days after he was struck in the left eye 
by a tree branch. He had previously started treatment with a 
combination of topical tobramycin (0.3%) and dexamethasone 
(0.1%) in addition to ciprofloxacin (0.3%). However the ocular 
redness persisted, and visual acuity worsened. At presentation, 
examination revealed a Snellen visual acuity of 20/30 with 
multifocal corneal infiltrates. Corneal cultures were obtained, 
and the previously-prescribed drops were changed to topical 
natamycin (5%), neomycin sulfate (0.5%), and moxifloxacin 
(0.5%) empirically. Two days later, visual acuity had dropped 
to hand motion with enlargement of the corneal ulcer and 
development of anterior segment infiltration. However there 
was no evidence of vitritis on B-scan ultrasound. An aqueous 
culture was obtained. An aqueous culture was obtained, and 
an empiric injection of voriconazole (100 ug) was given 
for presumed fungal invasion. Topical amphotericin B 
deoxycholate (0.15%) and systemic voriconazole (200 mg 
twice-daily) were added to the regimen. The aqueous culture 
revealed unspeciated Fusarium. Because the corneal and 
anterior chamber inflammation failed to improve and a 
follow-up B-scan ultrasound demonstrated new vitreous 
opacities, voriconazole (100 µg) was again injected into 
the vitreous cavity and the systemic voriconazole dose was 
increased to 400 mg twice-daily. However, the inflammation 
continued to worsen, which prompted surgical intervention 
with a penetrating keratoplasty, 20-gauge pars plana vitrectomy 
with lensectomy, and endoscopic exploration. Multiple subiris 
and ciliary body abscesses were removed using endoscopic 
visualization. Postoperative management included: topical 
amphotericin B deoxycholate (0.15%), natamycin (5%) and 
cyclosporine (1%), oral voriconazole (400 mg twice-daily), 
and two additional voriconazole (100 µg) injections through 
the pars plana. The corneal and intraocular inflammation 
slowly resolved, and the medication regimen was maintained 
for 3 months. Culture sensitivities, reported nearly a month 
after the surgery, revealed minimum inhibitory concentrations 
of 4 µg/mL for amphotericin B and natamycin and .8 µg/
mL for voriconazole. The best-corrected Snellen visual acuity 
was 20/60 after 5 years of follow-up.
Results
Each of the three consecutive cases was characterized by 
culture-positive Fusarium keratitis with subsequent anterior 
chamber invasion and vitreous involvement. The infection 
failed to respond to several treatments, including a variety 
of topical, intravitreal, and systemic antifungal medications. 
The endophthalmitis eventually cleared with a multimodal 
approach, including medical treatment with topical natamycin 
and amphotericin B deoxycholate, multiple intraocular 
voriconazole (VFEND®, Pfizer, New York, NY) injections, 
and high-dose, long-duration oral voriconazole (400 mg 
twice-daily). Surgical management included penetrating 
keratoplasty,   endoscopic-guided pars plana vitrectomy 
with subiris abscess removal, and lensectomy. In each case, 
clearance of the infection occurred after endoscopic removal 
of subiris and ciliary body abscesses. Both cases in which 
the sensitivity of Fusarium to voriconazole was measured 
Figure 1 Case 2. (A) The patient’s clinical condition, following 3 weeks of treatment with topical and oral antibiotics, with severe corneal infiltrate and hypopyon. (B) The 
patient’s eye 4 months after initial presentation, with a clear corneal graft and a quiet eye.
Notes: The clinical result represents a combined approach of aggressive medical treatment with topical, oral, and intravitreal antibiotics, in conjunction with endoscopic pars 
plana vitrectomy, involving lensectomy and removal of sub-iris abscesses, as well as two penetrating keratoplasties.
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demonstrated an MIC . 8 µg/mL. Despite this poor 
voriconazole sensitivity, the combined approach resulted in 
sterilization of the eye, and a final Snellen visual acuity score 
of 20/50 to 20/70.
Discussion
Fusarium endophthalmitis can result from penetrating 
trauma,6 keratitis,10 and intraocular surgery11 in immuno-
competent individuals. It can also occur endogenously in 
immunocompromised patients.9,12 The first two individuals 
in this case series developed endophthalmitis from Fusarium 
keratitis secondary to soft contact lens wear; the third patient 
acquired endophthalmitis from trauma-induced Fusarium 
keratitis.
Eradicating Fusarium endophthalmitis is notoriously dif-
ficult. Persistence of the infection despite standard treatments10 
or delayed recurrence of infection can occur for multiple 
reasons.13 First, Fusarium has high rates of resistance to some 
antifungal medications – which was the situation in at least two 
of these cases.5 Poor susceptibility to voriconazole is less com-
mon, but there are at least two other case reports that document 
resistance of Fusarium to voriconazole.14,15 Also, these cases 
raise the possibility that refractory cases might be secondary 
to undetected abscesses, which provide a nidus for persistent 
infection. Removal of the abscesses hidden beneath the iris 
was the event that, ultimately, initiated clinical improvement 
in each of these cases. Finally, topical corticosteroids were 
being used at presentation in all the cases. In the first two 
cases, corticosteroids were used postoperatively to prevent 
graft rejection. Studies suggest that topical corticosteroids 
might worsen Fusarium infection by inhibiting the antifungal 
phagocytic action of immune cells.16–18 Cyclosporine, which 
has both antifungal and antirejection properties, has dem-
onstrated effectiveness when used topically on therapeutic 
keratoplasties related to mycotic keratitis and may be a viable 
alternative to corticosteroids when a keratoplasty is required, 
as was the approach in Case 3.16,19
The older treatment modalities for ocular Fusarium 
infections are convoluted. Medical options have included: 
topical natamycin6 amphotericin B deoxycholate,6 and clotri-
mazole;6 subconjunctival amphotericin B deoxycholate6 and 
miconazole;6 intracameral amphotericin B deoxycholate;6 
intravitreal amphotericin B deoxycholate;6 systemic 
miconazole6 thiobendazole,6 fluconazole,10 ketoconazole,10 
amphotericin B deoxycholate,20 amphotericin B lipid com-
plex,21 and flucytosine.20 Surgical approaches have included: 
penetrating keratoplasty,10 lensectomy,10 iridectomy,10 and 
pars plana vitrectomy.6,10 Case reports11,20 have described 
some successes with various combinations of these treat-
ments. However, larger case series6,10 describe a predomi-
nantly dismal outcome. A number of these traditional medical 
and surgical modalities were incorporated without success 
in Case 1. Therefore, we switched to oral and intraocular 
voriconazole, in addition to novel surgical management. This 
new approach salvaged the eye, and was then applied to the 
two subsequent cases with relatively successful outcomes.
Voriconazole, with broad-spectrum antifungal properties, 
high oral bioavailability, and rapid systemic absorption, 
was approved by the US Food and Drug Administration in 
2002, for invasive Aspergillus, Fusarium, and Scedosporium 
infections. Although it is off-label for ocular indications, 
several small descriptive reports have suggested that it is safe 
and effective when directed against Fusarium infections in 
human eyes.4,22–25 The MIC of voriconazole towards ocular 
Fusarium isolates usually ranges between 2–8 µg/mL, with 
few cases of resistance.5 By contrast, Fusarium exhibits 
relatively high resistance rates to fluconazole, itraconazole, 
miconazole, ketoconazole, posaconazole, flucytosine, 
and amphotericin B deoxycholate.5,11 Voriconazole also 
demonstrates time-dependent activity, which suggests that 
maximizing the duration of exposure might optimize fungistatic 
activity.26 We attempted to achieve an intraocular concentration 
of voriconazole consistently in excess of the typical MIC by 
utilizing both systemic and intravitreal routes.
Systemically administered voriconazole in a non-inflamed 
human eye achieves an intravitreal concentration of 0.81–
1.12 µg/mL.23,27 We felt that an elevated dose of 400 mg, two 
times per day, might better maximize long-term intraocular 
concentrations. In conjunction with   the Infectious Disease 
Service, we monitored liver function tests weekly and were 
cognizant of potential adverse interactions with other sys-
temic medications. Tu et al described two cases of Fusarium 
endophthalmitis in which the patients were unable to tolerate 
oral voriconazole due to systemic t  oxicity. However, another 
review suggested that the majority of patients taking oral vori-
conazole for this indication tolerated the therapy long enough 
to achieve clearance of the infection.15,28 All of our patients 
were able to tolerate the higher dose for 3–4 months.
Repeated intraocular injections of voriconazole were 
added to maximize intraocular concentration. In keeping with 
previous reports discussing the safe dosing of intravitreal vori-
conazole, we injected 100 µg through the pars plana to achieve 
a presumed vitreous cavity concentration of approximately 
20–25 µg/mL.4,22,23,29–33 Injections were administered as fre-
quently as every 48 hours, since voriconazole has a relatively 
short half-life. In the rabbit vitreous, the half-life measured 
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2.5 hours. However, clearance may be more rapid in rabbits 
than in humans.34 The clearance rate most likely accelerated 
further following vitrectomy.35
In our patients, voriconazole was injected into the vitreous 
cavity instead of into the anterior chamber to maximize 
the duration of action and minimize anterior segment 
complications in these previously phakic eyes. However, 
a recent report described successful eradication of Fusarium 
in the anterior chamber when doses of voriconazole (100 µg) 
were injected intracamerally on a daily basis for up to 
8 days.24 Alternatively, topical voriconazole (1%) has good 
corneal penetration and was shown to achieve a concentration 
of at least 6.5 µg/mL in the anterior chamber.4,22,36 If initiated 
when the infection is limited to the anterior segment, these 
approaches may avoid the morbidity of more invasive 
procedures.
Once the infection reaches the vitreous, surgery is often 
needed to augment therapy.6 Pflugfelder et al reported that 
four of six patients (67%) with Fusarium endophthalmitis 
required penetrating keratoplasty, 83% required vitrectomy, 
100% required lensectomy, 67% required iridectomy, and 
67% were left with no light perception vision.6 Similarly, 
Dursun et al reported that nine of ten patients (90%) 
required penetrating keratoplasty, 40% required vitrectomy, 
50% required lensectomy, 10% required iridectomy, 
and 30% were left with no light perception vision.10 The 
cases described here all required penetrating keratoplasty, 
pars plana vitrectomy, and lensectomy. With endoscopic 
visualization, we identified and removed subiris and ciliary 
body abscesses during the vitrectomy, which were not 
apparent on clinical examination. This approach may have 
reduced the infectious load and allowed for improved access 
of voriconazole to any residual Fusarium. In addition, it may 
have prevented more drastic surgical interventions, such as a 
sector or complete iridectomy. As far as we know, this is the 
first report to describe subiris abscesses and removal in the 
management of Fusarium endophthalmitis.
In summary, we achieved successful resolution of 
three consecutive cases of Fusarium endophthalmitis with 
  functional visual outcomes. An aggressive therapeutic 
approach, including a combination of intravitreal and long-
term, high-dose systemic voriconazole, topical natamycin 
and amphotericin B deoxycholate, penetrating keratoplasty, 
lensectomy, and endoscopic guided pars plana vitrectomy 
resulted in the eradication of the Fusarium infections. This 
approach was developed after more traditional treatment 
modalities failed. Although this report is retrospective, 
uncontrolled, and describes a number of variables utilized 
in the treatment of Fusarium endophthalmitis, it is clear that 
the removal of subiris and ciliary body abscesses seemed to 
be the unifying event that initiated clinical improvement in 
each case. Thus, this combination of treatments, including 
the removal of abscesses, might decrease the morbidity of 
Fusarium endophthalmitis and allow for improved visual 
outcomes.
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